Nivolumab,Ipilimumab
BMS
['nivolumab', 'renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo']
clinical trial data in advanced clear cell renal cell carcinoma presented at asco #gu23 and led by 's meredith regan, scd, ( ) confirms the approach of limiting the duration of nivolumab immunotherapy to 2 years resulted in substantial treatment-free survival. 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090